This company listing is no longer active
O2T Stock Overview
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IVERIC bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.00 |
| 52 Week High | US$36.20 |
| 52 Week Low | US$9.37 |
| Beta | 1.1 |
| 11 Month Change | 2.27% |
| 3 Month Change | 44.00% |
| 1 Year Change | 226.44% |
| 33 Year Change | n/a |
| 5 Year Change | 1,521.62% |
| Change since IPO | 68.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| O2T | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -0.7% | -0.02% |
| 1Y | 226.4% | -17.2% | 8.2% |
Return vs Industry: O2T exceeded the German Biotechs industry which returned -6.5% over the past year.
Return vs Market: O2T exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| O2T volatility | |
|---|---|
| O2T Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: O2T's share price has been volatile over the past 3 months.
Volatility Over Time: O2T's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 163 | Glenn Sblendorio | ivericbio.com |
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases.
IVERIC bio, Inc. Fundamentals Summary
| O2T fundamental statistics | |
|---|---|
| Market cap | €5.01b |
| Earnings (TTM) | -€202.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-24.7x
P/E RatioIs O2T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| O2T income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$136.54m |
| Gross Profit | -US$136.54m |
| Other Expenses | US$86.37m |
| Earnings | -US$222.90m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 20.3% |
How did O2T perform over the long term?
See historical performance and comparison